What Does FDA Approval of a Digital Pathology System for Use in Primary Diagnosis Mean for the Pathology Industry? New Dark Daily Webinar to Provide Answers and Insights for Pathologists and Pathology Practice Administrators

08:00 EDT 1 Aug 2017 | Businesswire
Dark Daily

Experts agree that the FDA’s long-awaited clearance earlier this year of a Digital Pathology system for use in primary diagnosis is the trigger event for a wave of clinical, operational, and financial transformation. This decision has confronted every pathologist and pathology practice administrator with a fundamental question: how quickly will DP systems and whole slide imaging come to their group practice or medical laboratory?

“Digital pathology and whole slide images are poised to revolutionize the profession,” stated Robert L. Michel, Editor-In-Chief of The Dark Report. “Swift adoption of DP systems and WSI can give a pathology group considerable competitive advantage. It can mean stronger relationships with referring physicians, more case referrals, expanded market share, increased revenue, and greater compensation for the pathologist.”

To provide crucial insights on this topic, Dark Daily is conducting a timely webinar titled, “Primary Diagnosis with Digital Pathology Systems and Whole Slide Images: What Every Pathologist Needs to Know, Why It Will Be Disruptive, and How Innovative Pathology Groups Are Already Making Money with DP, on Thursday, August 17, 2017 at 1PM EDT.

Leaders in digital pathology will come together to deliver a concise assessment of the technology, how it is currently being used, and how to make informed decisions on when and how to introduce DP services to the hospital, client physicians, and patients. Chair of the webinar is Keith Kaplan, MD, Founder of The Digital Pathology Blog and recognized as one of the pathology profession’s thought leaders on web-based services, digital technologies, and new capabilities in molecular and genetic diagnostics.

Providing an up-to-the-minute lay of the land about DP systems and WSI will be Liron Pantanowitz, MD, Professor of Pathology and Biomedical Informatics at UPMC. He’ll discuss current capabilities of the technologies, with examples of their effective use in clinical care, plus informed insights about advances heading to the clinical market in the near future. Pantanowitz also has perspective on how DP will make it possible for group subspecialists to generate more case referrals from the region, the nation, and internationally.

Last will be case studies by pathology groups that are using DP and WSI to deliver enriched diagnostic services to referring physicians, while winning new clients and generating new sources of revenue.

This webinar comprises concentrated learning and essential information including:

  • What the FDA’s clearance of the Philips IntelliSite Pathology Solution for primary diagnosis allows and what it does not
  • Useful steps a pathology group can take to evaluate the benefits versus costs of acquiring and using a DP system
  • The hurdles to adoption and use of DP systems and WSI, and overcoming those hurdles
  • Actions the pathology team should take to assess DP systems and develop a viable ROI

For more information about this webinar and to view details including presenter biographies and pricing, click here.

The Dark Intelligence Group, Inc.
Chris Garcia, 512-264-7103


More From BioPortfolio on "What Does FDA Approval of a Digital Pathology System for Use in Primary Diagnosis Mean for the Pathology Industry? New Dark Daily Webinar to Provide Answers and Insights for Pathologists and Pathology Practice Administrators"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...